Webb20 sep. 2024 · 'This GMP-grade leukopak product introduction underscores BioIVT's commitment to being a high quality, global immune cell provider,' said BioIVT CEO Dr. Richard Haigh. 'BioIVT customers have... Webb8 aug. 2024 · WESTBURY, N.Y., Aug. 8, 2024 /PRNewswire/ -- BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired...
BioIVT expands into new therapy areas with Fidelis acquisition
Webb13 sep. 2024 · Led by CEO Dr. Richard Haigh, BioIVT is a provider of research models and value-added research services for drug discovery and development. The solutions enable scientists to understand the... Webb2 aug. 2024 · BioIVT, LLC (“BioIVT”), a leading global provider of biospecimens, cell and gene therapy related products, and research models and services for drug development purposes, today announced the promotion of Richard Haigh, PhD, to Chief Executive Officer (CEO) effective August 1. greenwich convenient medical care center
BioIVT Announces Promotion of Dr. Richard Haigh to CEO
Webb2 aug. 2024 · Most searched biographies at BioIVT. Richard Haigh, Chief Executive Officer; Gerrit Smith, Senior Vice President, Global Operations; Christopher Black, Senior Vice President, ADME-Tox; Popular executive movements at BioIVT. Jeff Gatz, Chief Executive Officer, is retiring (posted on August 2 2024). Create your alert to follow the executive … Webb20 sep. 2024 · “This GMP-grade leukopak product introduction underscores BioIVT’s commitment to being a high quality, global immune cell provider,” said BioIVT CEO Dr. Richard Haigh. “BioIVT customers have always been able to scale their research up and out using our global collection network of recallable donors. Webb1 aug. 2024 · Haigh joined BioIVT in May 2024 as Chief Operating Officer and brings over 27 years’ experience in the life science research and diagnostics space covering products, consumables, and services, including over 15 years … foals cctv